Sinocelltech Group Ltd (688520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinocelltech Group Ltd (688520) has a cash flow conversion efficiency ratio of 0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-100.18 Million ≈ $-14.66 Million USD) by net assets (CN¥-730.66 Million ≈ $-106.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sinocelltech Group Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 688520 current and long-term liabilities for a breakdown of total debt and financial obligations.
Sinocelltech Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocelltech Group Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scorpio Tankers Inc.
F:S0QA
|
0.044x |
|
Cargotec Oyj
HE:CGCBV
|
0.087x |
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
0.054x |
|
Anhui Jingcheng Copper Share Co Ltd
SHE:002171
|
-0.009x |
|
Shyam Metalics and Energy Limited
NSE:SHYAMMETL
|
0.031x |
|
Seadrill Limited
NYSE:SDRL
|
-0.014x |
|
Shenzhen Colibri Technologies Co Ltd
SHE:002957
|
0.026x |
|
Hybio Pharmaceutical
SHE:300199
|
0.177x |
Annual Cash Flow Conversion Efficiency for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sinocelltech Group Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 688520 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥134.94 Million ≈ $19.75 Million |
CN¥125.12 Million ≈ $18.31 Million |
0.927x | +47.52% |
| 2023-12-31 | CN¥-605.81 Million ≈ $-88.65 Million |
CN¥-380.80 Million ≈ $-55.72 Million |
0.629x | -64.42% |
| 2022-12-31 | CN¥-242.19 Million ≈ $-35.44 Million |
CN¥-427.91 Million ≈ $-62.62 Million |
1.767x | -52.70% |
| 2021-12-31 | CN¥-230.99 Million ≈ $-33.80 Million |
CN¥-862.82 Million ≈ $-126.26 Million |
3.735x | +508.95% |
| 2020-12-31 | CN¥588.36 Million ≈ $86.10 Million |
CN¥-537.41 Million ≈ $-78.64 Million |
-0.913x | +93.45% |
| 2019-12-31 | CN¥34.80 Million ≈ $5.09 Million |
CN¥-485.10 Million ≈ $-70.99 Million |
-13.938x | -477.54% |
| 2018-12-31 | CN¥-23.84 Million ≈ $-3.49 Million |
CN¥-88.02 Million ≈ $-12.88 Million |
3.692x | +764.28% |
| 2017-12-31 | CN¥167.84 Million ≈ $24.56 Million |
CN¥-93.28 Million ≈ $-13.65 Million |
-0.556x | -10.91% |
| 2016-12-31 | CN¥80.38 Million ≈ $11.76 Million |
CN¥-40.28 Million ≈ $-5.89 Million |
-0.501x | -- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more